SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB-Reference-Cited by-同舟云学术

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

Published:2017-10 Issue:10 Volume:37 Page:1847-1858
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

Avery Robert L.,Castellarin Alessandro A.,Steinle Nathan C.,Dhoot Dilsher S.,Pieramici Dante J.,See Robert,Couvillion Stephen,Nasir Ma'an A.,Rabena Melvin D.,Maia Mauricio,Van Everen Sherri,Le Kha,Hanley William D.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference58 articles.

1. The biology of VEGF and its receptors;Ferrara;Nat Med,2003

2. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology;Stewart;Mayo Clin Proc,2012

3. Intravitreal aflibercept for diabetic macular edema;Korobelnik;Ophthalmology,2014

4. Ranibizumab and bevacizumab for neovascular age-related macular degeneration;Martin;N Engl J Med,2011

5. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema;Nepomuceno;Am J Ophthalmol,2013

Cited by 250 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe Intraocular Inflammation After Intravitreal Injection of Faricimab: A Single-Site Case Series of Six Patients;American Journal of Ophthalmology;2025-01

2. Clinical Risk Factors for Retinopathy of Prematurity Reactivation after Intravitreal Antivascular Endothelial Growth Factor Injection;The Journal of Pediatrics;2024-10

3. Experiencia con el uso de bevacizumab intravítreo en el manejo de la retinopatía del prematuro tipo I en un país latinoamericano;Archivos de la Sociedad Española de Oftalmología;2024-09

4. Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country;Archivos de la Sociedad Española de Oftalmología (English Edition);2024-09